Description

IFA Norex Anfepramona 50mg

THERAPEUTIC INDICATIONS It is indicated as an adjunct in the treatment of exogenous obesity, associated with a hypocaloric diet and exercise.

INDICATIONS FOR THERAPEUTIC USE

It is recommended as adjunctive therapy in treating exogenous obesity in conjunction with a low-calorie diet and physical activity.

CLINICAL PHARMACOLOGY

After oral administration, amfepramone is fastly absorbed from the gastrointestinal tract. It is then extensively metabolized via a complex pathway of biotransformation involving N-dealkylation and reduction. Many of amfepramone’s metabolites are biologically active and may participate in the therapeutic action of IFA Norex Anfepramona 50mg.

According to several studies, amfepramone and its metabolites can cross the blood-brain barrier and the placenta.

It has been indicated that 75% of the dose was recovered in the urine within 24 hours after administration. The plasma half-life of its metabolites is expected to be between 4 and 6 hours. Amfepramone and its metabolites are both eliminated mostly through renal excretion.

CONTRAINDICATIONS

IFA Norex Anfepramona 50mg should not be given to patients who are hypersensitive to amfepramone or have an idiosyncrasy to sympathomimetic amines, states of agitation, or emotionally unstable people who are prone to or have a history of drug or alcohol abuse. This is because it can result in a hypertensive crisis. Patients should wait 14 days after giving monoamine oxidase before giving IFA Norex Anfepramona 50mg.

Patients who suffer from glaucoma, hyperthyroidism, superior arteriosclerosis or excessively high blood pressure, severe kidney disease, children younger than 12 years old, pregnancy, or lactation are not candidates for treatment with this medication.

GENERAL PRECAUTIONS

It is imperative that the recommended dose not be exceeded; however, the drug must be stopped as soon as the affected individual stops losing weight.

Should only be used with extreme caution in severe hypertension and cardiovascular disease, including arrhythmias.

It has been hypothesized that the amfepramone disaster could also cause an increase in the frequency of seizures in some epileptic patients. As a result, these patients must be carefully monitored to determine whether or not they should stop taking the medication altogether.

Prolonged use can lead to dependence, which, when the treatment is stopped abruptly, can cause withdrawal syndrome.

Abuse of drugs and dependence on them are both possible outcomes of exposure to compounds chemically related to amphetamines and other stimulant capsules. There were reviews written by individuals who suggested being dependent on amfepramone psychologically. After taking extremely dangerously high doses, hallucinations have only occurred highly infrequently.

There were multiple cases of people experiencing toxic psychosis after using amfepramone excessively. Even though it was said that they did not exceed the recommended dose, some people were found to have toxic psychosis in a minimal number of cases.

After stopping taking the drug, the psychosis became fleeting and eventually went away completely. The vast majority of these topics had a history of abusing other pills, such as amphetamine and fermetrazinc, and a good number are characterized by having an unstable personality.

In a few instances, amfepramone was given via intravenous administration. Even in patients who took the amfepramone abusers orally, an undesirable level of hysteria and agitation decreased due to the drug’s effects. The addicts reported that they felt relatively little euphoria and were therefore disappointed.

Amfepramone users who abused the drug reported that after taking it for 24 to 72 hours, additional doses of the substance did not produce euphoria but rather anxiety. This was another one of the drug’s side effects. If tolerance develops, the recommended amount should not be administered to boost the effect; instead, the medicine should be stopped altogether if at all possible.

Patients on amfepramone may find that their ability to concentrate while engaging in potentially hazardous tasks, such as operating heavy machinery or driving a motor vehicle, is diminished. It is critical to provide patients with information regarding these conditions.

Before starting any new treatment, we ask that you check in with your primary care physician